PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Cost reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine competitive advantage.
100.00%
Positive growth while CRVO shows decline. John Neff would investigate competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
10.75%
R&D growth less than half of CRVO's 35.86%. David Dodd would verify if efficiency advantage is sustainable.
-21.32%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.47%
Operating expenses growth while CRVO reduces costs. John Neff would investigate differences.
1.47%
Total costs growth while CRVO reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
6.88%
D&A change of 6.88% while CRVO maintains D&A. Bruce Berkowitz would investigate efficiency.
-1.39%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-1.47%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-3.00%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-1.89%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.89%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
2.63%
EPS growth while CRVO declines. John Neff would investigate advantages.
2.63%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
3.22%
Share count change of 3.22% while CRVO is stable. Bruce Berkowitz would verify approach.
3.22%
Diluted share change of 3.22% while CRVO is stable. Bruce Berkowitz would verify approach.